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Immunity
Santosh K. Panda and Marco Colonna*
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, United States
Innate lymphoid cells (ILCs) are innate counterparts of T cells that contribute to immune
responses by secreting effector cytokines and regulating the functions of other innate
and adaptive immune cells. ILCs carry out some unique functions but share some tasks
with T cells. ILCs are present in lymphoid and non-lymphoid organs and are particularly
abundant at the mucosal barriers, where they are exposed to allergens, commensal
microbes, and pathogens. The impact of ILCs in mucosal immune responses has been
extensively investigated in the gastrointestinal and respiratory tracts, as well as in the
oral cavity. Here we review the state-of-the-art knowledge of ILC functions in infections,
allergy and autoimmune disorders of the mucosal barriers.
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INTRODUCTION
ILCs are a family of lymphocytes comprising the innate counterparts of T cells. They are poised
to secrete cytokines that respond swiftly to pathogenic tissue damage and shape subsequent
adaptive immunity (1). While lacking antigen-specific receptors, ILCs detect changes in the
microenvironment through receptors for cytokines that are released upon tissue damage, as well
as a broad range of receptors for nutrient components, microbial products, lipid mediators, and
neuronal transmitters. Found in both lymphoid and non-lymphoid tissues, ILCs are primarily
tissue resident cells and are particularly abundant at the mucosal surfaces of the intestine and
lung, whereas they are extremely rare in peripheral blood (2, 3). Based on the signature cytokines
they produce, their phenotype, and their developmental pathways, ILCs are divided into three
major groups: ILC1s, ILC2s, and ILC3s. Two additional immune cell types, NK cells and lymphoid
tissue inducer (LTi) cells, are generally included in the ILC family because their phenotypic,
developmental and functional properties overlap considerably with those of ILC1s and ILC3s,
respectively (4).
ILC1s secrete IFN-γ in response to IL-12, IL-15, and IL-18. IFN-γ promotes the ability of
macrophages and DCs to eliminate intracellular bacteria and to present antigens by inducing
expression of MHC and adhesion molecules. The features and functions typical of ILC1s largely
overlap with those of NK cells, which also produce IFN-γ. In mice, ILC1s and NK cells both
express NKp46 and NK1.1: in humans, both cell types express CD56 and NKp46 (5). A subset
of human ILC1s that lacks CD56 and expresses CD127 has also been reported (6). In both humans
and mice, ILC1s express markers of tissue residency, such as CD49a and CD103, as well as tissue
retention, like CD69, whereas NK cells express markers indicative of recirculation through blood,
including CD62L, CCR7, and S1PR (4, 7). Based on higher expression of perforin and granzymes,
NK cells have more cytolytic potential than do ILC1s (4, 8). ILC1s can kill target cells through the
cell death-inducingmolecule TRAIL. Inmice, the differentiation of ILC1s requires the transcription
factors Hobit and T-bet, whereas NK cells rely on T-bet and Eomes (9–11). However, the expression
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of these transcription factors in human ILC1s and NK cells
does not follow the clear pattern seen in mice. In fact, while
human intraepithelial ILC1s express Eomes (5, 12), human
hepatic NK cells do not (13), Moreover, differential expression of
Eomes during distinct developmental stages of NK cells has been
observed (14).
ILC2s, the innate counterparts of Th2, secrete type-2 cytokines
such as IL-5, IL-9, IL-13, and amphiregulin in response to TSLP,
IL-25, and IL-33. IL-13 plays crucial roles in the expulsion
of helminths. Moreover, IL-13 and amphiregulin help repair
the tissue damage engendered by helminth and viral infections
(15–17). In humans, ILC2s express CRTH2, KLRG1, ST2, and
CD25 (18, 19). Although human and mouse ILC2s share many
surface markers, expression of CD44 and CD161 differs between
the two. Mouse ILC2s express CD44 but not CD161 whereas
human ILC2s invert this phenotype and express CD161 but not
CD44 (4, 20). ILC2 development depends on the transcription
factors GATA3, RORα, and TCF-1 in mice (21–23). GATA3 is
also required for maintenance of ILC2 number in vivo and its
effector function in mice (22, 24). Further, it was demonstrated
that GATA3 is required for activation of human ILC2s (25).
Although ILC2s are considered homogenous, they are classified
into two groups based on their responsiveness to IL-33 and IL-
25. IL-33 responsive ILC2s present in the steady state are called
natural ILC2s (nILC2), whereas IL-25 responsive ILC2s elicited
upon exposure to IL-25 or helminth infection are referred to
as inflammatory ILC2s (iILC2) (26, 27). nILC2s are demarcated
by elevated expression of Thy1 and ST2 along with relatively
little KLRG1; in comparison, iILC2s express more KLRG1,
less Thy1 and almost no ST2 on the cell surface (26, 27).
Another subpopulation of ILC2s that produce IL-10 (ILC210)
has also been identified (28). ILC210 can be induced by IL-
33 or papain and are transcriptionally distinct; moreover this
population undergoes contraction when the stimulus is removed
and the few remaining ILC210 can be promptly activated upon
restimulation (28).
Because ILC3s produce IL-22 and IL-17 in response to IL-
23 and IL-1β, they are considered the innate counterparts of
Th17. IL-22 stimulates the secretion of antimicrobial peptides
by epithelial cells and mucus production by goblet cells, thereby
supporting barrier integrity in the intestine (Figure 1) (29–31).
Moreover, it promotes the differentiation of epithelial cells from
intestinal stem cells (32). IL-17 promotes granulopoiesis and
the secretion of neutrophil chemoattractant (33). ILC3s also
produce additional cytokines such as IL-26 (in humans), GM-
CSF and TNF-α (34, 35). GM-CSF sustains the generation and
survival of myeloid cells, like gut DCs, that promote generation of
tolerogenic commensal-specific T cells (35). The differentiation
of ILC3s is driven by the transcription factors RORγt and AHR
(36, 37). Like ILC3s, LTi are dependent on RORγt and secrete
IL-22 and IL-17. In the embryo, LTi drive the development of
secondary lymphoid organs, including lymph nodes and Peyer’s
patches, through the expression of lymphotoxin (LT) that engages
LTβ receptor on stromal organizer cells. In the adult, LTi cells
cluster to form intestinal cryptopatches, which expand into B
cell-rich isolated lymphoid follicles (37–40). In humans, ILC3s
express NKp44, CD127, c-Kit, and CCR6. In mice, ILC3s express
also CD127, c-Kit, but include CCR6+NKp46− LTi as well as
CCR6−NKp46− and CCR6−NKp46+ subsets.
Since ILCs mainly populate mucosal sites, this review focuses
on how these cells typically contribute to maintenance of barrier
integrity and protection against various pathogenic challenges,
as well as their propensity to promote allergic and autoimmune
diseases when inappropriately stimulated. We individually
review the impact of ILCs in the respiratory and gastrointestinal
tracts as well as the oral mucosa and discuss potential targeting of
ILCs for therapeutic intervention in human diseases.
ILCs IN THE RESPIRATORY TRACT
MUCOSA AND LUNGS
ILCs are present throughout all segments of the respiratory
tract. While ILC2s are the predominant ILC population in mice,
ILC3s dominate the human respiratory tract (2, 41). However,
the composition and functions of ILC subsets dynamically
change during experimental mice models of pathology and
human diseases.
ILCs IN RESPIRATORY INFECTIONS
Experiments in mice have shown that ILC2s promote epithelial
and goblet cell proliferation and mucus production in the
H1N1 influenza virus infection model through secretion of
amphiregulin and IL-13 (15). These ILC2 functions contribute
to restore lung epithelial integrity. Accordingly, antibody-
mediated depletion of ILC2s compromised lung function during
H1N1 influenza infection. However, a study by Chang et al.
demonstrated that ILC2s play a pathogenic role through IL-13
production in the H3N1 influenza infection model that induces
airway hyper-reactivity, a cardinal feature of asthma (42). H3N1-
induced airway hyper-reactivity was attenuated in Il13−/− mice,
whereas adoptive transfer of ILC2s restored this response (42).
The reason for this discrepancy in the impact of ILC2s is yet to
be deciphered; perhaps the differential virulence of the H1N1 and
H3N1 viral strains used in these models is responsible. ILC2s also
provide defense against helminth infection of the lung through
the production of IL-9, IL-13, and amphiregulin (Figure 1) (16,
17, 43). A recent study by Huang et al. demonstrated that the
KLRG1hi ST2− ILC2s that protect the lung from helminth-
induced tissue damage originate in the intestine and migrate
from the intestine to the lung during infection (17).
NK cells and ILC1s contribute to immune responses against
viruses through secretion of IFN-γ (Figure 1). NK cells play dual
roles during influenza infection. Increased virus accumulation
in the lung was observed in the absence of NK cells (44–46).
However, depletion of NK cells rendered mice more resistant
and able to survive severe influenza infection (47). Furthermore,
adoptive transfer of NK cells obtained from influenza-infected
lungs into mice newly infected with influenza exacerbated the
disease (47). ILC1s protect from Sendai virus and influenza
infection by robust secretion of IFN-γ in experimental models
(48). Beneficial roles for NK cells, ILC1s and ILC2s have been
demonstrated in other mouse models of lung viral infections,
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FIGURE 1 | Role of ILCs in different mucosae. Different ILC subsets play beneficial and detrimental roles in different mucosae: protection against various infections,
tolerance against innocuous antigens, induction of allergy, IBD, and cancer. NK cells and ILC1s block viral and intracellular bacterial infections by secreting IFN-γ.
However, ILC1s promote COPD and IBD in respiratory and intestinal mucosa, respectively. ILC2s contribute to worm expulsion and tissue repair in both respiratory
and intestinal mucosa during helminth infection. Further, these cells repair viral induced lung injury by secreting amphiregulin. On the other hand, ILC2s promote
allergic inflammation in lung and nasal polyps. ILC3s play dual role in both respiratory and intestinal mucosa. These cells confer protection against extracellular
bacterial infection by secreting IL-22 which induces production of anti-microbial peptides by epithelial cells. ILC3s block oral fungal infection in an IL-17-dependent
manner. These cells also promote tolerance against commensal and dietary antigens through MHC-II mediated antigen presentation. However, inappropriate
activation of ILC3s can play a detrimental role by instigating allergy in the respiratory mucosa, as well as IBD and cancer in the intestinal mucosa.
such as rhinovirus (49, 50) and respiratory syncytial virus (RSV)
(49, 51). Finally, ILC3s have also been implicated in lung
infections and inflammation. Lung ILC3s play a protective role
in S. pneumonia infected mice through secretion of IL-17 and IL-
22 (Figure 1) (52). Despite the abundance of studies in mouse
models, the role of ILCs in human respiratory infections is yet to
be deciphered (Table 1).
ILCs IN ASTHMA
Multiple studies concur that ILC2s play a pathogenic role during
lung allergy and inflammation (Figure 1) (73, 74). Mice lacking
ILCs, T cells, and B cells developed less airway inflammation than
did mice lacking only T cells and B cells in the papain-induced
eosinophilic asthma model (56, 75). Furthermore, adoptive
transfer of ILC2s was sufficient to induce airway inflammation
in the absence of B and T cells (75). ILC2s initiate allergic lung
inflammation by secreting IL-13, which promotes migration of
activated DCs to the draining lymph node where they prime
Th2 differentiation (56). Lung ILC2s promoted proliferation and
antibody production by B1 and B2 cells in vitro and contributed
to enhanced production of IgM in vivo in an experimental model
of polysaccharide-mediated nasal allergy (76). Moreover, ILC2s
acquired a memory-like phenotype after primary encounter with
allergen and more readily promoted allergic inflammation in the
lung upon secondary encounter with unrelated allergens than did
naïve ILC2s (77).
In human, expansion of ILC2s and elevated type-2 cytokines
have been observed in a variety of patients with allergic
asthma (Table 1). Approximately twice as many ILC2s were
found in the peripheral blood of allergic asthmatic patients
than in healthy controls (60). In addition, ILC2s from allergic
asthmatic patients were hyper-responsive to IL-33 and IL-25 and
secreted significantly higher amounts of IL-5 and IL-13 than did
ILC2s from healthy controls (60). Smith et al. reported higher
percentages of ILC2s in the blood and sputum of prednisone-
dependent severe eosinophilic asthma patients than in the
blood of asymptomatic patients with steroid-naive mild atopic
asthma or healthy controls (78). Respiratory allergen challenge of
patients with allergic asthma elicited a sudden increase and rapid
activation of ILC2s primed to secrete IL-5 and IL-13 (79). Further
supporting a role for ILC2s in allergic asthma, the frequency of
ILC2s and the levels of IL-33 in the bronchoalveolar lavage (BAL)
of patients with allergic asthma were positively correlated with
severity of the disease (80). Likewise, the percentage of ILC2s
was higher in the peripheral blood of patients with eosinophilic
asthma and positively correlated with eosinophil counts in the
sputum (81). Similarly, the frequency of ILC2s was higher in the
blood and BAL of children with severe therapy-resistant asthma
than in children with recurrent lower respiratory tract infections
(82). Finally, an increase of ILC2s in the BAL of patients with
idiopathic pulmonary fibrosis has also been observed (83).
How other ILCs impact asthma is less clear. ILC3s have been
suggested to play a pathogenic role in asthma patients. Numbers
of IL-17-producing ILC3s in the human lung positively correlate
with severity of the disease (57). IL-22 production by ILC3s has
also been implicated in asthma pathogenesis, as asthma patients
have increased levels of IL-22 compared to healthy controls (84).
In mice, NK cells and ILC1s that produce IFN-γ inhibit ILC2
expansion and type-2 cytokine production (85, 86) and hence
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TABLE 1 | Role of ILCs in different mucosa of humans and mice.
Mucosa Host Cells
NK cells ILC1 ILC2 ILC3 References





(45), (48), (15, 52)




ND ND ND (53)





ND ND (54, 55)
Human Number increased in
peripheral blood and
lung





















Mouse Unclear ND Worm expulsion and
tissue repair
ND (16, 17)
Human Unclear ND ND ND





Human ND ND ND ND
Homeostasis Mouse ND ND ND Maintain tissue
homeostasis
(32, 35)
Human ND ND ND ND
IBD Mouse Unclear Promotes IBD ND Promotes IBD (5, 65, 66)
Human Unclear Accumulated in the
inflamed gut
ND Accumulated in the
inflamed gut
(5, 67)





Human Unclear ND ND Reverse correlation
between the number
of ILC3 and disease
severity.
(70, 71)






Human ND ND ND ND
ND, Not defined.
might help control the disease. Consistent with this, depletion
of NK cells during the early stages of papain-induced lung
allergy in mice resulted in increased ILC2-mediated cytokine
production, which exacerbated pathology (58). Furthermore,
Han et al. demonstrated that IFN-γ inhibits expansion of IL-13
producing ILC2s and attenuates the development of rhinovirus-
induced asthma pathology in baby mice (87). Altogether, these
studies suggest that ILC1s and NK cells attenuate the initiation
and progression of allergic inflammation in the lung in mouse
models. However, the role of NK cells in human allergic asthma
is unclear. A human study documented fewer NK cells in the
peripheral blood of severe asthma patients than in healthy
controls, as well as an enrichment of the CD56bright NK cell
subset in the BAL of asthmatic patients, whereas no significant
difference in the frequency of ILC2s was detected in the blood
of controls, severe, and mild asthma patients (88). One report
described increased frequency of an unusual population of
NK cells that produces IL-4 rather than IFN-γ in the blood
of asthmatic patients (89). In contrast, another study showed
that heightened IFN-γ responses in the airways of patients
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were associated with severe asthma, which often involves mixed
granulocytic inflammation that includes neutrophils as well as
eosinophils (90). Supporting a role of IFN-γ in initiation of
airway hyper responsiveness these authors showed that in a
mouse model mimicking human severe asthma IFN-γ−/− mice
failed to exhibit the symptoms of severe asthma as compared
to wild type controls (90). Further research in human patients
focusing on NK cells, ILC1s, and ILC2s in both blood and
inflamed tissuemight decipher how the balance between different
subsets of ILCs impacts asthma pathogenesis.
ILCs IN ALLERGIC RHINITIS
ILC2s have also been implicated in the pathogenesis of allergic
rhinitis. The frequency of ILC2s was elevated in nasal polyps
characteristic of chronic rhino-sinusitis and aspirin-exacerbated
respiratory disease and positively correlated with disease severity
(18, 41, 59, 91, 92). Recruitment of ILC2s to the nasal mucosa
upon a nasal mucosal challenge in subjects with allergic rhinitis
was demonstrated in human volunteers (93). TSLP produced
by epithelial cells and IL-4 produced by eosinophils induces
ILC2 activation and secretion of IL-4, IL-5, and IL-13; this
activates eosinophils and thereby elicits a positive feedback loop.
Disrupting this loop with anti-IL-5 antibodies was beneficial
for treating chronic rhino-sinusitis in humans (94, 95). More
ILC2s have been noted in the peripheral blood of allergic rhinitis
patients than in blood from healthy controls (96, 97). Moreover,
the response to house dust mite-specific immunotherapy
negatively correlated with ILC2 numbers; patients with a good
response to the allergen-specific immunotherapy had relatively
few ILC2s (97). Furthermore, subcutaneous allergen therapy
resulted in fewer circulating ILC2s in patients with allergic
rhinitis (98). In contrast, NK cells appear to play a beneficial role
in allergic rhinitis, as patients had fewer circulating CD56bright
NK cells than did healthy controls (99).
ILCs IN CHRONIC OBSTRUCTIVE
PULMONARY DISEASE OF THE LUNG AND
CANCER
Chronic obstructive pulmonary disease (COPD) is a disorder
caused by cigarette smoke or long-term inhalation of noxious
gases, which damage the upper and lower airways, eventually
causing bronchitis and emphysema (100). Studies in mice and
humans have demonstrated that lung resident ILC2s acquire
an ILC1 phenotype and secrete IFN-γ during COPD (41, 54).
Furthermore, ILC1 numbers were increased in the peripheral
blood of patients with severe COPD (Table 1). Additionally, a
high ILC1-to-ILC2 ratio in the blood of COPD patients positively
correlated with severity of the disease (54). Shikhagaie et al.
reported significantly increased numbers of neuropilin+ ILC3s
in the lungs of patients with COPD, which were associated
with formation of ectopic lymphoid aggregates (40). Further
supporting a role for ILC3s in COPD, IL-17 was found to
accumulate in the lungs of COPD patients (101).
In contrast to their deleterious effect in COPD, ILCs may be
beneficial in lung cancer. ILC3s have been reported to congregate
in human non-small cell lung carcinoma tissues where they
may play a protective role by promoting the formation of
tertiary lymphoid structures (102). The role of NK cells in lung
cancer remains confusing, but should become more well-defined
as better reagents/methods to detect NK cells and relevant
activating and inhibiting receptors are developed and widely
used. An early study that employed CD57, which is not specific
for NK cells, found that the presence of tumor infiltrating
CD57+ cells was associated with a better prognosis in patients
with primary squamous cell lung carcinoma (SCLC) (103). A
more recent study suggested that infiltration of CD16+CD56+
NK cells in the tumor periphery correlated with increased
survival time of patients with non-small-cell lung carcinoma
(NSCLC) (104). This study also noted that intra-tumoral NK
cells downregulated activating receptors, including NKG2D, and
upregulated the inhibitory receptor NKG2A in a mouse model
of metastatic human large cell lung cancer. Consistent with this,
Platonova et al. reported that intra-tumoral NK cells in NSCLC
patients have an altered phenotype, with decreased expression
of activating receptors such as NKp30, NKG2D, NKp80 and
increased expression of the inhibitory receptor NKG2A (105).
Along these lines, Carrega et al. found that most NK cells
infiltrating NSCLC were CD56bright CD16−; the intra-tumoral
NK cells had less cytotoxic potential than did NK cells in the
peripheral blood and lung, but retained the ability to secrete
IFN-γ and TNF-α (106). However, Hodge et al. reported that
NK cells (as well as NKT, CD4+ and CD8+ T cells) isolated
from lung cancer tissue secreted less perforin, granzyme B,
IFN-γ, TNF-α after stimulation than did NK, NKT, and T cells
isolated from healthy tissue (107). Finally, Christmas et al. found
that while the frequency of peripheral NK cells did not differ
between patients with NSCLC or SCLC and healthy controls, NK
cells isolated from cancer patients had diminished expression of
NKp46, CD25, and perforin A and were functionally impaired in
terms of cytoxicity and cytokine production (108). Collectively,
these studies suggest that the tumor microenvironment either
recruits NK cells with limited cytotoxic potential or, more likely,
directly alters the phenotype of NK cells in order to escape
from NK cell-mediated anti-tumor responses. Further research
in human patients is warranted to delineate the precise role of
ILCs in lung cancer.
THE IMPACT OF ILCs ON INTESTINAL
MUCOSA
ILC3s are the most abundant subset of ILCs in both the fetal and
adult human intestine (8). In contrast, the distribution pattern
of ILC1s and ILC2s changes during development. In the fetal
intestine ILC2s prevail over ILC1s, whereas ILC1s assume the
dominant role in the adult intestine (8, 18). ILCs are unevenly
distributed throughout the segments of the gastro-intestinal (GI)
tract. The upper GI tract, e.g., esophagus, is enriched with
ILC1s, whereas the distal part of the ileum and colon are chiefly
populated by ILC3s (109).
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ILCs IN GASTROINTESTINAL TRACT
INFECTIONS
The role of ILCs in intestinal infection has been demonstrated in
various experimental models (Table 1); ILC3s participate in the
immune responses toCitrobacter rodentium, Clostridium difficile,
Salmonella enterica, Listeria monocytogenes, and Toxoplasma
gondii (10, 39, 63, 110–112). Further work has shown that
ILC3s restrict colonization of segmented filamentous bacteria
in the gut (113) and inhibit the invasion of Alcaligenes species
into Peyer’s patches (114). ILC3s counter bacterial infections
through secretion of IL-22, which stimulates epithelial cells to
produce antimicrobial peptides (Figure 1) (31). Furthermore, IL-
22 induces fucosyltransferase 2 expression in intestinal epithelial
cells, which promotes fucosylation of surface proteins that are
shed into the lumen. These fucosylated proteins release fucose,
which is metabolized by microbes as an energy source. Fucose
metabolism has been shown to suppress virulent gene expression
in commensal bacteria (115), and Goto et al. demonstrated that
the absence of epithelial cell fucosylation renders mice more
susceptible to Salmonella infection (62). IL-22 production is
mainly stimulated by IL-23 and IL-1β produced by inflammatory
monocytes, macrophages and DCs. TNF-like ligand 1A produced
by mononuclear phagocytes upon interaction with microbiota in
the gut also induces IL-22 production by ILC3s and promotes
healing of mucosal layer during DSS-induced acute colitis (116).
ILC1s and NK cells help combat intracellular pathogens
such as T. gondii, L. monocytogenes, Salmonella typhimurium
and viruses through IFN-γ production (10, 117, 118). ILC1s
cooperate with ILC3s in providing protection against intestinal
C. difficile infection (112); accordingly, rapid infection and
death ensue in the absence of IFN-γ and IL-22. By secreting
IL-5 and IL-13, ILC2s induce goblet cell differentiation and
mucus production that propels worm expulsion and protects
from tissue damage (61, 64, 119, 120). Finally, while most
studies have focused on bacterial infections, ILCs may also
impact intestinal viral infections. Studies in mice have shown a
protective role for ILC3s during rotavirus infections, in which
IL-22 synergizes with IFN-λ in inducing STAT1 activation (121).
Recently, a cross-sectional study reported that the colons of HIV-
1 infected patients are enriched with NKp44+ILC1s that produce
IFN-γ (122).
While the above studies support a critical role for ILCs
in maintaining barrier integrity that protects mice from a
variety of infections, one study has suggested that ILCs are
completely redundant. Vely et al. studied SCID patients following
allogeneic hematopoietic stem cell transplants that reconstituted
the T cell compartment but not the ILC compartment. These
patients did not manifest an increased risk of infections and
other complications (123). Further research in human subjects
addressing these issues is warranted.
ILCs IN AUTOIMMUNITY
ILCs have been extensively studied in intestinal autoimmune
disorders, particularly inflammatory bowel disease (IBD)
(Table 1). Crohn’s disease (CD) and ulcerative colitis (UC)
are the two main forms of IBD that affect distinct layers of
the gut wall and colonic mucosa. Although the mechanisms
underpinning IBD remain incompletely understood, immune
responses against commensal microbes in the intestine have
long been implicated. The role of ILC3s in IBD is unclear.
Several papers have proposed that ILC3s may contribute to
autoimmunity. IL-23, the key activator of ILC3s, has been
shown to drive colitis (124). Accumulation of ILC3s in inflamed
colons of Helicobacter hepaticus infected mice has been reported
(65). Moreover, mice either depleted of or genetically modified
to lack ILC3s were resistant to colitis (65). Similarly, IL-17-
producing ILC3s have been shown to drive colitis, whereas
administration of anti-IL-17 antibodies ameliorated disease
(125). ILC3s also drove intestinal inflammation and pathology
in the anti-CD40 model of innate colitis mice through secretion
of IL-22 and GM-CSF (66). In agreement with this study,
Pearson et al. demonstrated that ILC3-mediated production of
GM-CSF recruits inflammatory monocytes into the intestine,
which sustain intestinal inflammation (126). Corroborating
these findings in humans, IL-17-producing ILC3s have been
found to accumulate in the inflamed colons of patients with
CD (127). Other studies have proposed a tolerogenic role for
ILC3s during intestinal inflammation. ILC3s express MHC class
II and can present commensal bacteria to T cells. However,
because they lack costimulatory molecules, ILC3s are unable
to elicit commensal-specific CD4+ T cells and, in fact, induce
T cell tolerance and mitigate inflammation in mouse models
(128, 129). Consistent with this, unusually low expression of
MHC-II has been observed on colonic ILC3s from pediatric IBD
patients (128). A similar role for ILC3s in maintaining tolerance
against dietary and innocuous commensal antigens has also been
reported (35, 129, 130).
ILC1s have also been implicated in human IBD (Table 1).
CD127+ lamina propria ILC1s and CD127− intra-epithelial
ILC1s amass in the inflamed intestine of CD patients (5, 8).
Interestingly, expansion of IFN-γ producing cells with an NK cell
phenotype in the lamina propria of CD patients was accompanied
by a reciprocal decrease in IL-22 producing NKp44+ ILC3s
(131). Li et al. also observed that the frequency of ILC1s
rises in the inflamed ileum of CD patients, whereas frequency
of ILC3s declines (132). The increase in ILC1 frequency
at the cost of ILC3s might be due to plasticity of ILC3s,
which transdifferentiate into ILC1s under the influence of IL-
12 and/or IL-23 produced by myeloid cells (12). Increased
frequency of Lin−CD127+ ILC1s in the colons of patients
with IBD and primary sclerosing cholangitis has also been
observed. Furthermore, these authors have demonstrated that the
frequency of ILC1s drops in the blood of patients, suggesting that
ILC1s are recruited into the inflamed tissue (133).
ILC2s have also been implicated in intestinal inflammation.
Expansion of IL-13 producing ILC2s has been shown to play
a detrimental role in oxazolone-induced colitis (134). However,
expansion of amphiregulin-producing ILC2s has been shown
to contribute to tissue repair during DSS-induced colitis (135).
Thus, ILC2s may either promote or block intestinal pathogenesis,
depending on the disease setting. ILC2s have been noted
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in intestinal samples from CD patients (19). Interestingly,
these ILCs secreted IFN-γ, reflecting the plasticity of ILC2s
during intestinal inflammation. Increased ILC2 frequency that
positively correlates with severity of the disease has been
observed in patients with eosinophilic oesophagitis (136). While
accumulation of ILCs in the intestine of CD patients has been
demonstrated, whether ILCs are involved in UC remains unclear.
In fact, Gwela et al. reported no difference in ILC frequencies
between UC patients and healthy controls (133).
In addition to autoimmunity, intestinal tissue damage can be
induced by chemotherapy and radiotherapy. In this case, ILC3s
help repair intestinal damage by secreting IL-22 (68, 137). During
graft-vs.-host disease (GVHD), which can occur in leukemic
patients after allogeneic hematopoietic stem cell transplant,
allogeneic T cells can attack and destroy ILC3s, thereby depleting
intestinal IL-22. In mice with acute GVHD, ILC3s secreted
significantly less IL-22, resulting in impaired epithelial functions
(Table 1) (68). Corroborating a role for ILC3s and ILC3-secreted
IL-22 in tissue repair and resolution of inflammation during
GVHD, fewer ILC3s were observed in patients with acute or
chronic GVHD than in patients that did not develop GVHD,
(71). Furthermore, recovery of gut homing CD69+ activated
ILC3s was associated with a lower incidence of GVHD (71).
Finally, infusion of donor ILC2s after bone marrow transplant
reduced the lethality of GVHD up to 70% and enhanced the
barrier function of the GI tract in an allogenic stem cell transplant
model (69). Altogether, these studies support a beneficial role for
ILC2s and ILC3s in prognosis of GVHD.
ILCs IN INTESTINAL CANCER
It has been known for long time that IBD patients have an
increased risk of intestinal cancer due to chronic inflammation
(138). Given that ILCs accumulate in the intestinal mucosa
during IBD, they could contribute to the inflammatory
environment and may play a pro-tumorigenic role. Indeed, the
key activator of ILC3s, IL-23, and the ILC3 effector cytokines
IL-17 and IL-22 are associated with both experimental and
clinical tumorigenesis (Figure 1) (139–142). In contrast to
ILC3s, NK cells and ILC1s may have anti-tumorigenic effects
through secretion of IFN-γ. A decreased frequency of NK
cells expressing NKp30, NKp46, and NKG2D paralleled by an
increased frequency of ILC2s was noted in the peripheral blood
of gastric cancer patients in comparison to healthy controls
(143). Similarly, serum levels of IFN-γ in gastric cancer patients
were lower than those found in healthy donors (144, 145).
Although infiltration of NK cells into gastric cancer tissues is
scarce (146), the presence of intratumoral NK cells correlated
with a better prognosis (147). While these studies suggest that
ILCs are involved in the pathogenesis of intestinal cancer,
further studies in human patients is required to address their
exact role.
ILCs IN THE ORAL MUCOSA
Like the intestinal mucosa, the oral mucosa is populated
with commensal microflora and exposed to dietary antigens
and pathogens. Thus, ILCs present in the oral mucosa
may help maintain barrier function and protect against
pathogenic infections. Human ILC3s and intraepithelial ILC1s
were originally identified in tonsils, which are secondary
lymphoid tissues coated by the oral mucosa (5, 34). ILCs
have been also found in human gingivae. Approximately
10–15% of total CD45+ cells identified were ILCs and
most of them were IFN-γ secreting ILC1s (148). A recent
study by Brown et al. demonstrated the presence of all
FIGURE 2 | ILCs as potential therapeutic targets. Because of their various roles in promoting or attenuating pathogenesis, ILCs may be potential therapeutic target.
Infiltration of NK cells into intestinal cancer is associated with better prognosis, therefore increasing NK cell infiltration and potentiating NK cell functions in tumors
might be beneficial. Hyperactivation of both ILC1 and ILC3 promote COPD and IBD. Regulation of pathogenic cytokine production or antibody mediated depletion of
these cells might be a potential treatment option. Similarly, antibodies targeting type-2 cytokines produced by ILC2 may be promising in the treatment of allergy and
asthma patients. Both ILC2 and ILC3 ameliorate clinical symptoms and play protective roles in GVHD. Expansion of ILC2 and ILC3 numbers by therapeutic
intervention might be helpful to control GVHD.
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three groups of ILCs in the murine gingivae (149). ILC3s
provided protection against oropharyngeal infection with
Candida albicans through production of IL-17A and IL-17F
induced by IL-23 (Figure 1) (72); thus, both Rorγ t−/− mice
lacking ILC3s and mice depleted of ILC3s by antibody treatment
suffered severe infection (72). IFN-γ-producing ILC1s and
NK cells have been found in the oral mucosa of macaques.
During simian immunodeficiency virus infection, expansion
of ILC1s and increased IFN-γ production were noted in
the oral draining lymph nodes and tonsils whereas NK cells
remained unchanged (150). Future research will decipher the
impact of ILCs in oral immune responses to commensals and
dietary antigens.
TARGETING ILCs FOR THERAPY
A strong rationale for developing therapies specifically targeting
ILCs, such as depleting or agonistic antibodies, depends on
whether ILCs play unique, non-redundant roles in the context of
various diseases, which is yet to be firmly established. However,
evidence from both experimental mice models and humans has
suggested that therapeutic targeting of ILCs might be beneficial
for autoimmune disorders. Depletion of Thy-1 positive ILCs was
beneficial for treatingH. hepaticus induced colitis (65). Similarly,
depletion of ILC2s blocked the development of papain-induced
allergy (75). When ILCs and T cells have redundant functions, an
alternative option is to neutralize the effector cytokines produced
by both ILCs and T cells. Blockade of the IL-17 receptor or
neutralizing IL-17 and IFN-γ in several clinical trials failed
to ameliorate IBD (151, 152). However, targeting both IL-17
and IFN-γ bore promising results in preclinical models (65).
Blockade of cytokines that stimulate IL-17 and IFN-γ secretion,
such as IL-12 and IL-23 or IL-23 alone, has also been effective for
treating CD patients (153, 154). Since GVHD is associated with
fewer IL-22-producing ILC3s, enhancement of ILC3 numbers
and function might be explored for the treatment of GVHD
(Figure 2) (68, 71).
Several attempts have been made to explore the efficacy
of targeting ILC2s in respiratory diseases. Anti-IL-5 and
anti-IL-4 receptor α treatments have had promising effects
in treating patients suffering from chronic rhinosinusitis
with nasal polyps and eosinophilic asthma (94, 155, 156).
Similarly, inhibiting ILC2 functions with CRTH2 antagonists
can restore lung function in asthma patients (Figure 2)
(157, 158). Further research and well-designed clinical studies
should help delineate the efficacy of targeting ILCs in various
mucosal diseases.
FUTURE PERSPECTIVES
ILCs appear to contribute significantly to human health and
disease, playing beneficial roles in some mucosal infections and
GVHD, while aggravating pathology in IBD and COPD. Are
ILCs a valid therapeutic target? To address this question, it is
important to understand whether ILCs play unique roles or
are largely redundant with T cells. Studies in mouse models
have provided limited answers, as they are mainly performed
in RAG-deficient mice that lack adaptive responses. Animal
models in which ILCs are selectively ablated in the presence
of intact adaptive responses are underdeveloped. Most human
studies describe single timepoint assays that provide a snapshot
of ILCs at a particular stage of the disease. Longitudinal studies
addressing multiple subsets of ILCs at different stages of disease
is warranted to provide a clearer picture of their impact. For
instance, while NK cells seem to control lung ILC2 expansion
in asthma, it is important to understand whether NK-ILC2
cross-talk occurs at a particular stage or throughout the disease.
Similarly, ILC3 secretion of IL-17 and IFN-γ seems to be
detrimental in IBD, whereas IL-22 secretion may be protective.
Thus, it is essential to examine the ratio of ILC3s producing IL-
17/IFN-γ and IL-22 at different stages of the disease. Although
ethical constraints and limitations of available tissue restrict
human studies, further analysis including diverse age groups
and focusing on different stages of disease would help better
understand the role of ILCs as well as how they might be targeted
for the therapy of mucosal diseases.
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